Checkpoint Inhibitors The Diagnosis and Treatment of Side Effects

Heinzerling L, De Toni EN, Schett G, Hundorfean G, Zimmer L (2019)

Publication Type: Journal article, Review article

Publication year: 2019

Journal

Deutsches Ärzteblatt international Deutscher Ärzte-Verlag

Book Volume: 116

Pages Range: 119-+

Journal Issue: 8

DOI: 10.3238/arztebl.2019.0119

Abstract

Background: Treatment with checkpoint inhibitors such as anti-programmed death-1 (anti-PD-1), anti-PD-ligand 1 (anti-PD-L1), and anti-cytotoxic T-Iymphocyte antigen-4 (anti-CTLA-4) antibodies can prolong the survival of cancer patients, but it also induces autoimmune side effects in 86-96% of patients by activating the immune system. In 17-59% of patients, these are severe or even life-threatening.

Authors with CRIS profile

Lucie Heinzerling Department of Dermatology Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

Universität Duisburg-Essen (UDE) DE Germany (DE) Ludwig-Maximilians-Universität (LMU) DE Germany (DE)

How to cite

APA:

Heinzerling, L., De Toni, E.N., Schett, G., Hundorfean, G., & Zimmer, L. (2019). Checkpoint Inhibitors The Diagnosis and Treatment of Side Effects. Deutsches Ärzteblatt international, 116(8), 119-+. https://doi.org/10.3238/arztebl.2019.0119

MLA:

Heinzerling, Lucie, et al. "Checkpoint Inhibitors The Diagnosis and Treatment of Side Effects." Deutsches Ärzteblatt international 116.8 (2019): 119-+.

BibTeX: Download